Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ELAN 
Elanco Animal Health (ELAN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/14/2025: ELAN (4-star) is a STRONG-BUY. BUY since 109 days. Simulated Profits (69.06%). Updated daily EoD!
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
15 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $20.55
1 Year Target Price $20.55
| 6 | Strong Buy |
| 1 | Buy |
| 8 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 86.01% | Avg. Invested days 64 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 10/14/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 9.96B USD | Price to earnings Ratio 22.77 | 1Y Target Price 20.55 |
Price to earnings Ratio 22.77 | 1Y Target Price 20.55 | ||
Volume (30-day avg) 15 | Beta 1.65 | 52 Weeks Range 8.02 - 21.76 | Updated Date 10/13/2025 |
52 Weeks Range 8.02 - 21.76 | Updated Date 10/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.88 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 9.68% | Operating Margin (TTM) 6.85% |
Management Effectiveness
Return on Assets (TTM) 0.98% | Return on Equity (TTM) 6.83% |
Valuation
Trailing PE 22.77 | Forward PE 20.53 | Enterprise Value 13839776479 | Price to Sales(TTM) 2.22 |
Enterprise Value 13839776479 | Price to Sales(TTM) 2.22 | ||
Enterprise Value to Revenue 3.09 | Enterprise Value to EBITDA 9.55 | Shares Outstanding 496813702 | Shares Floating 492938555 |
Shares Outstanding 496813702 | Shares Floating 492938555 | ||
Percent Insiders 1.05 | Percent Institutions 108.83 |
Upturn AI SWOT
Elanco Animal Health
Company Overview
History and Background
Elanco Animal Health was founded in 1954 as a division of Eli Lilly and Company. It focused on animal health products. In 2019, it became an independent, publicly-traded company through an IPO. Significant milestones include the acquisition of Bayer Animal Health in 2020, expanding its product portfolio and global reach.
Core Business Areas
- Companion Animal Health: Focuses on preventing and treating diseases and other conditions in pets, offering products such as parasiticides, vaccines, and therapeutics.
- Food Animal Health: Develops solutions for livestock, including cattle, poultry, and swine, focusing on improving animal health, welfare, and production efficiency, including products like antibiotics, vaccines, and feed additives.
Leadership and Structure
Elanco Animal Health is led by CEO Jeff Simmons. The organizational structure includes key departments such as R&D, Commercial Operations, and Finance.
Top Products and Market Share
Key Offerings
- Advantage family of products: Parasiticides for flea and tick control in pets. A well known offering for flea control. Competitors include Frontline, Revolution, and Bravecto. Market share data is not readily available without subscription services.
- Interceptor Plus: Heartworm preventative and broad-spectrum dewormer for dogs. It competes with Heartgard, Revolution, and Trifexis. Market share data is not readily available without subscription services.
- Gallimycin: Antibiotic used in poultry production. Competitors include Zoetis and Boehringer Ingelheim. Market share data is not readily available without subscription services.
Market Dynamics
Industry Overview
The animal health industry is growing, driven by increasing pet ownership, rising demand for animal protein, and growing awareness of animal welfare. The industry is characterized by innovation in pharmaceuticals, vaccines, and diagnostics.
Positioning
Elanco Animal Health is a major player in the animal health industry, with a broad portfolio of products and a global presence. Its competitive advantages include its R&D capabilities and its distribution network.
Total Addressable Market (TAM)
The global animal health market is estimated to be over $50 billion. Elanco Animal Health is well-positioned to capture a significant share of this market.
Upturn SWOT Analysis
Strengths
- Broad product portfolio
- Global presence
- Strong R&D capabilities
- Experienced management team
- Established distribution network
Weaknesses
- High debt levels due to the Bayer acquisition
- Integration challenges from acquisitions
- Exposure to regulatory risks
- Dependence on key products
Opportunities
- Growing demand for animal health products
- Expanding into emerging markets
- Developing innovative products
- Acquiring complementary businesses
- Pet humanization driving premium products
Threats
- Competition from other animal health companies
- Price pressures from generics
- Changes in regulations
- Economic downturns
- Disease outbreaks
Competitors and Market Share
Key Competitors
- Zoetis (ZTS)
- Merck Animal Health (MRK)
- Boehringer Ingelheim
Competitive Landscape
Elanco faces intense competition from larger, more established players. It needs to innovate and differentiate its products to gain market share. Bayer acquisition expands their competitive power, but they still hold a lot of debt.
Major Acquisitions
Bayer Animal Health
- Year: 2020
- Acquisition Price (USD millions): 7600
- Strategic Rationale: The acquisition of Bayer Animal Health significantly expanded Elanco's product portfolio, geographic reach, and R&D capabilities, making it the second largest animal health company globally.
Growth Trajectory and Initiatives
Historical Growth: Historical Growth data available via subscription service. Limited publicly accessible data.
Future Projections: Future Projections data available via subscription service. Limited publicly accessible data.
Recent Initiatives: Recent Initiatives data available via subscription service. Limited publicly accessible data.
Summary
Elanco Animal Health is a major player in the animal health market but faces challenges due to its high debt load and integration efforts from the Bayer acquisition. Its broad product portfolio and global presence provide a strong foundation for growth, but it must innovate to compete with larger rivals like Zoetis. The company does not pay a dividend, but may provide good returns if they improve performance in the near future. It is important to monitor its debt and integration progress.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Elanco Animal Health Investor Relations
- Company SEC Filings
- Industry Reports
- Market Research Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share and financial data may be estimates and subject to change. Consult with a financial professional before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Elanco Animal Health
Exchange NYSE | Headquaters Greenfield, IN, United States | ||
IPO Launch date 2018-09-20 | President, CEO & Director Mr. Jeffrey N. Simmons | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 9000 | Website https://www.elanco.com |
Full time employees 9000 | Website https://www.elanco.com | ||
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. It offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio, Credelio Cat, Credelio Plus, Interceptor Plus, Doncit, Drontal, Drontal Plus, and Trifexis trademarks; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark. The company also provides farm animal products that help farmers improve animal health and wellbeing, and raise livestock, such as cattle, swine, and poultry. In addition, it offers medicated feed additives, injectable antibiotics, vaccines, insecticides and enzymes, and others under the Rumensin, Baytril, and Experior trademarks for cattle; and under the Maxiban and Monteban trademarks for the control and prevention of intestinal disease in poultry. Further, the company offers other pet health products for cats and dogs under the Atopica, Milbemax, Onsior, and TruCan trademarks; and other farm animal products for poultry, cattle, and swine under the AviPro, Catosal, Denagard, Hemicell, Pulmotil, and Surmax tradmarks. It sells its products to third-party distributors and independent retailers; and directly to farm animal producers and veterinarians. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.